Co-Diagnostics, Inc.
Research Co-Diagnostics, Inc. (CODX) on Bullrun: market cap USD 3.16M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCODX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 3.16M
- Financial periodQ2 2026
- RevenueUSD 166.13K
- Net income-USD 6.28M
- Free cash flow-USD 7.17M
- Gross margin72.7%
Valuation Snapshot
latest market cap is USD 3.16M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 622.49K | -USD 46.90M | -USD 29.84M | 64.3% | -35.25 | USD 11.88M | USD 1.24M | USD 20.63M |
| FY2024 | USD 3.92M | -USD 37.64M | -USD 29.90M | 74.5% | -37.22 | USD 2.94M | USD 2.15M | USD 53.88M |
| FY2023 | USD 6.81M | -USD 35.33M | -USD 23.45M | 38.6% | -36 | USD 14.92M | USD 2.99M | USD 86.01M |
| FY2022 | USD 34.22M | -USD 14.24M | USD 5.14M | 84.0% | -13.5 | USD 22.97M | USD 347.92K | USD 114.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-20 | USD 3.16M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.62M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 24.79M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 40.67M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 77.91M | 164.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 9.06B | 218.7 | n/a | n/a |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Co-Diagnostics, Inc.'s market cap?
Co-Diagnostics, Inc.'s market capitalization is USD 3.16M.
What does Co-Diagnostics, Inc. do?
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus.